| Literature DB >> 16773161 |
Karen E Stc Hamilton1, Frank M Sullivan, Peter T Donnan, Rex Taylor, Divine Ikenwilo, Anthony Scott, Chris Baker, Sally Wyke.
Abstract
PURPOSE: To investigate the set up and operation of a Managed Clinical Network for cardiac services and assess its impact on patient care.Entities:
Year: 2005 PMID: 16773161 PMCID: PMC1395516 DOI: 10.5334/ijic.135
Source DB: PubMed Journal: Int J Integr Care Impact factor: 5.120
Summary of patient characteristics (values are numbers (%) of participants unless stated otherwise)
| Characteristic | Pre MCN | Post MCN | |
|---|---|---|---|
| Gender | Men | 59 (60.8) | 76 (72.4) |
| Women | 38 (39.2) | 29 (27.6) | |
| Mean (SD) age at event | 63 (9) | 63 (9) | |
| Attend rural practice | 41 (42.3) | 38 (36.2) | |
| Have co-morbidity | 29 (29.9) | 28 (26.9) | |
| Median Carstairs Depcat score | 3 | 3 | |
Summary of clinical data in relation to MCN protocols
| Area | MCN Protocol | Result | Difference between pre and post MCN p-value | |
|---|---|---|---|---|
| Pre MCN (n=97) | Post MCN (n=105) | |||
| Immediate aspirin | All to receive immediate aspirin | 63.6% | 67.7% | 0.56 |
| Thrombolysis | All to be considered for thrombolysis | 48.3% | 59% | 0.14 |
| 50% to achieve door to needle target (≤30 minutes) | 31% | 45.6% | 0.14 | |
| Achieve pain to needle target (≤90 minutes) | 15% | 32.7% | 0.05 | |
| Median pain to needle times (hh:mm [range]) | 2:27 [10:45] | 2:09 [10:17] | 0.2 | |
| Discharge medication | 70% on antiplatelet agents | 97.6% | 97.9% | 0.89 |
| 70% on betablockade | 60.2% | 68.1% | 0.28 | |
| 70% on ACEI | 90.2% | 88.4% | 0.70 | |
| 70% on Statin (with cholesterol >5.00) | 78.6% | 88.7% | 0.10 | |
| Cardiac rehabilitation | All seen by rehab nurse pre discharge | 96.4% | 96.8% | 0.87 |
| All have out-patient rehab arranged pre discharge | 88.8% | 92.4% | 0.41 | |
| All attend out-patient rehab programme | 75.9% | 76.4% | 0.94 | |
| Secondary prevention at 6 months post MI | 70% on antiplatelet agents | 98.8% | 97.8% | 0.62 |
| 70% on betablockade | 61.3% | 75% | 0.05 | |
| 70% on ACEI | 87.3% | 85.4% | 0.71 | |
| 70% on Statin (with cholesterol >5.00) | 80.3% | 95.5% | 0.007 | |
Refers to chi-squared test of difference for pre-post comparisons.
°: Refers to Mann-Whitney test of difference for pre-post comparisons.
Results of multiple linear regression* of aggregated weekly outcomes pre and post introduction of the MCN
| Outcome | Difference in level post vs. pre | Difference in slope post vs. pre | ||
|---|---|---|---|---|
| Regression Coefficient (se) | p-value | Regression coefficient (se) | p-value | |
| Immediate aspirin | −35.9 (16.9) | 0.037 | 0.937 (0.561) | 0.099 |
| Median pain to needle time (log transformed) | −1.207 (0.605) | 0.051 | 0.025 (0.010) | 0.014 |
Adjusted for time trends, autocorrelation and co-morbidity.
Summary of economic data
| Cost | Median (Range) Cost Per Patient | Difference between pre and post MCN p-value | |
|---|---|---|---|
| Pre MCN | Post MCN | ||
| Hospital costs | £1,601 (£629,£7,290) | £1,565 (£805,£9,845) | 0.18 |
| Follow up costs | £424 (£231,1,246) | £413 (£212,£1,445) | 0.61 |
| Total costs | £2,055 (£629,£7,290) | £2,053 (£805,£9,845) | 0.35 |
Refers to p-value from linear regression.